Table 1: Participant information and individual trial results.

Participant Information

Stool PCR Resultsa

Quantity of C. diff Toxin Genes (genome equivalents per gram of stool)

CDI Symptom Severity Results (1 = Mild, 5 = Severe)

ID

Age

Sex

First-Time CDI?

Toxin A

Toxin B

Diarrhea

Bloating

Abdominal Pain / Cramping

Nausea

Pre-Trial

Post-Trial

Pre-Trial

Post-Trial

Pre-Trial

Post-Trial

Pre-Trial

Post-Trial

Pre-Trial

Post-Trial

Pre-Trial

Post-Trial

1

58

F

Yes

1.02 x 106

<dl

1.51 x 106

<dl

0

0

3

0

0

0

0

0

2

75

M

No

<dl

<dl

2.01 x 103

<dl

5

2

3

3

4.5

4

5

0

3

79

F

No

3.65 x 106

<dl

5.45 x 106

<dl

0

0

4

0

0

0

0

0

4

54

F

No

3.29 x 105

9.73 x 102

9.67 x 106

4.64 x 104

0

0

2

2

0

0

0

0

5

4

M

Yes

5.32 x 105

<dl

1.30 x 106

<dl

2

0

0

0

1

0

1

0

6

38

F

Yes

<dl

<dl

1.12 x 103

<dl

0

0

2

1

0

0

0

0

7

47

F

Yes

<dl

<dl

2.67 x 103

<dl

0

NRb

0

NR

0

NR

0

NR

aPCR Clinical Reference = 1.00 x 103

bNR = No Response

Note: None of the participants reported prior hospitalization for CDI or experienced a fever during the trial. Two participants (participant 1 and 5) reported dehydration at trial onset, but hydration status remained unchanged throughout the study. Additional symptom questions not presented here were either universally negative or inconsistently reported; full details are available in the supplementary data.